Therapex develops patient-specific anti-cancer drugs through molecular testing that targets cancer-causing proteins and mutations, focusing on treatment-resistant solid tumors. The company employs advanced drug design techniques, including PROTAC technology, to create therapies for patients with limited treatment options.
Funding
Funding not disclosed
Founders
Product
Problem
Many solid tumors develop resistance to standard treatments, leaving patients with limited options and a poor prognosis. Current therapies often fail to address the underlying molecular drivers of cancer growth and drug resistance, leading to disease progression.
Solution
Therapex is developing patient-specific anti-cancer drugs by targeting cancer-causing proteins and mutations identified through molecular testing. The company focuses on treatment-resistant solid tumors and employs advanced drug design techniques, including PROTAC (PROteolysis TArgeting Chimera) technology, to create innovative therapies. These therapies aim to overcome drug resistance by directly degrading disease-causing proteins, offering new hope for patients with limited treatment alternatives.
Target Audience
The primary target audience includes patients with treatment-resistant solid tumors, particularly non-small cell lung cancer, and the oncologists treating these patients.
Features
- Development of 4th generation EGFR inhibitors to overcome resistance in non-small cell lung cancer (NSCLC)
- PROTAC technology platform for targeted protein degradation of "undruggable" proteins
- Focus on overcoming resistance to existing therapies like Tagrisso in EGFR-mutated NSCLC
- Preclinical development of novel immunotherapies for solid tumors
- ADC (Antibody-Drug Conjugate) technology development for targeted drug delivery
- In-silico modeling for rapid lead discovery